This report on global Listeria monocytogenes infections treatment market studies various drugs used for treatment of Listeria monocytogenes infection’s along with pipeline analysis of upcoming potential drugs. According to Centers for Disease Control and Prevention (CDC), Listeriosis, a serious infection usually caused by eating food contaminated with the bacterium Listeria monocytogenes, is an important public health problem in the United States. In addition, CDC estimates that approximately 1600 illnesses and 260 deaths due to listeriosis occur annually in the United States. Thus, drug pipeline of Listeria monocytogenes infections treatment market comprises potential drugs which are more target-specific and possess innovative properties. 

For the purpose of this study, the various infection types studied include bacteremia, meningitis, brain abscess, gastroenteritis, endocarditis, and others. Market size estimates and forecast for these segments for the period 2013 to 2023 are provided in terms of USD Mn along with the respective CAGRs for the period 2016 to 2023, considering 2015 as the base year.

The pipeline analysis for Listeria monocytogenes infections treatment market comprises projected market sales of Phase III drugs estimated till 2023. The phase III drugs included in the pipeline analysis are Carbavance (The Medicines Company), Telavancin (Theravance Biopharma Antibiotics, Inc.), Daptomycin (Merck & Co.), Prulifloxacin (Merck & Co.), and DTaP-IPV/Hib combined vaccine (Sanofi S.A.). The report also covers qualitative information associated with the drugs under phase II and I of the clinical trials.

The geographic segmentation of the global Listeria monocytogenes infections treatment market is performed for the regions North America, Europe, Asia Pacific and Rest of the World markets. The regions are also further sub-segmented on the basis of major countries. Market size estimates and forecast for these segments for the period 2013 to 2023 are provided in terms of USD Mn along with the respective CAGRs for the period 2016 to 2023, considering 2015 as the base year.

Type of Infection Segmentation Analysis

In 2010, a study carried out by European researchers published in the World Health Organization’s (WHO) The Lancet Infectious Diseases suggested that, Listeria monocytogenes was estimated to infect 23,150 people worldwide and killed 5,463 of them, or 23.6 percent.  According to market experts, Listeria causes significantly fewer deaths worldwide than Salmonella Typhi (216,500 annual deaths) or non-typhoidal Salmonella (155,000), but it does cause a far higher rate of death.

Listeriosis is a serious, potentially fatal infection caused by Listeria species. Listeria species are found throughout the environment, residing in soil, water, sewage, vegetation, wild animal feces, farms, and food-processing facilities. In year 2015 it was observed that Bacteremia and Meningitis were the most prevalent diseases in the world, the major factors assisting the market growth were rise in prevalence of foodborne diseases, unawareness in case of personal and environmental sanitation in developing and developed countries, and improper cleaning and processing of vegetables and meat products. According to Centers for Disease Control and Prevention (CDC), Over 1.2 million cases of bacterial meningitis are estimated to occur worldwide each year. The incidence and case-fatality rates for bacterial meningitis vary by region, country, pathogen, and age group. Without treatment, the case-fatality rate can be as high as 70%, and one in five survivors of bacterial meningitis may be left with permanent squealed including hearing loss, neurologic disability, or loss of a limb.

North America was observed as the largest market for Listeria monocytogenes infections treatment in the base year 2015. Despite strict regulatory policies, L. monocytogenes still has a major detrimental influence in the food industry, causing food product recalls and disease outbreaks. According to a report published by United States Department of Agriculture (USDA) suggests that, every year approximately 48 million people become ill from foodborne illnesses in the United States. Even though just 1,600 people, on average, are sickened by foodborne Listeria, it ranks 3rd among causes of foodborne illness-associated deaths in the United States, causing nearly 19% of such deaths (255 in a typical year). It imposes an estimated USD 2.8 billion in economic burden in a typical year of which almost USD 2.1 billion is due to deaths. Rising prevalence of foodborne diseases, low grade sanity conditions at manufacturing site, improper storage and transportation of food materials and low awareness associated with the foodborne diseases in under developed and developing countries are the key factors assisting the market growth of Listeria monocytogenes infections treatment market globally during the forecast period 2016 – 2023.  

Historical & Forecast Period

This study report represents analysis of each segment from 2022 to 2032 considering 2023 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2024 to 2032.

The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.

Research Methodology

The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. key data point that enables the estimation of Listeria Monocytogenes Infections Treatment market are as follows:

• Research and development budgets of manufacturers and government spending
• Revenues of key companies in the market segment
• Number of end users and consumption volume, price and value.
• Geographical revenues generate by countries considered in the report
• Micro and macro environment factors that are currently influencing the Listeria Monocytogenes Infections Treatment market and their expected impact during the forecast period.

Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top down and bottom-up approach for validation of market estimation assures logical, methodical and mathematical consistency of the quantitative data.

Key questions answered in this report

• What are the key micro and macro environmental factors that are impacting the growth of Listeria Monocytogenes Infections Treatment market?
• What are the key investment pockets with respect to product segments and geographies currently and during the forecast period?
• Estimated forecast and market projections up to 2032.
• Which segment accounts for the fastest CAGR during the forecast period?
• Which market segment holds a larger market share and why?
• Are low and middle-income economies investing in the Listeria Monocytogenes Infections Treatment market?
• Which is the largest regional market for Listeria Monocytogenes Infections Treatment market?
• What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?
• Which are the key trends driving Listeria Monocytogenes Infections Treatment market growth?
• Who are the key competitors and what are their key strategies to enhance their market presence in the Listeria Monocytogenes Infections Treatment market worldwide?